In mouse models, treatment with the RIPK1 inhibitor necrostatin-1 or the endothelial cell-specific deletion of RIPK3 reduced tumor cell-induced endothelial necroptosis, tumor cell extravasation, and metastasis. This evidence concerns the gene RIPK3 and neoplasm.